Atossa Genetics Inc Cash Flow Conversion Efficiency
Atossa Genetics Inc cash flow conversion efficiency. Based on the latest financial reports, Atossa Genetics Inc (ATOS) has a cash flow conversion efficiency ratio of -0.121x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.00 Million) by net assets ($49.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Atossa Genetics Inc (2009–2024)
Cash flow conversion efficiency of Atossa Genetics Inc from 2009 to 2024. This chart illustrates how Atossa Genetics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Atossa Genetics Inc for real-time trading data and today's change.
Atossa Genetics Inc Cash Flow Conversion Ratio Explained
Atossa Genetics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Atossa Genetics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Atossa Genetics Inc ranked by their cash flow conversion efficiency. Also see market value of Atossa Genetics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Egeplast Ege Plastik Ticaret ve Sanayi AS
IS:EPLAS
|
-0.008x |
|
Delta Resources Ltd
V:DLTA
|
-0.144x |
|
DAYTHREE DIGITAL BERHAD
KLSE:0281
|
0.065x |
|
JPEL Private Equity Ltd
LSE:JPEL
|
0.023x |
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
N/A |
|
Eagon Ind
KO:008250
|
0.033x |
|
Acrinova AB Series B
ST:ACRI-B
|
0.018x |
|
Next Hydrogen Solutions Inc.
V:NXH
|
-0.339x |
Annual Cash Flow Conversion Efficiency for Atossa Genetics Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Atossa Genetics Inc from 2009 to 2024. Review ATOS free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $71.48 Million | $-21.03 Million | -0.294x | -27.88% |
| 2023-12-31 | $91.02 Million | $-20.94 Million | -0.230x | -30.74% |
| 2022-12-31 | $117.96 Million | $-20.76 Million | -0.176x | -47.58% |
| 2021-12-31 | $138.14 Million | $-16.47 Million | -0.119x | +72.00% |
| 2020-12-31 | $27.17 Million | $-11.57 Million | -0.426x | +38.62% |
| 2019-12-31 | $13.16 Million | $-9.13 Million | -0.694x | +31.83% |
| 2018-12-31 | $8.81 Million | $-8.96 Million | -1.018x | -7.10% |
| 2017-12-31 | $6.94 Million | $-6.59 Million | -0.950x | +45.24% |
| 2016-12-31 | $3.10 Million | $-5.37 Million | -1.735x | +53.46% |
| 2015-12-31 | $3.74 Million | $-13.95 Million | -3.729x | -235.56% |
| 2014-12-31 | $9.50 Million | $-10.56 Million | -1.111x | -33.43% |
| 2013-12-31 | $10.60 Million | $-8.83 Million | -0.833x | -10.53% |
| 2012-12-31 | $5.18 Million | $-3.90 Million | -0.754x | +66.35% |
| 2011-12-31 | $1.56 Million | $-3.49 Million | -2.239x | -632.62% |
| 2010-12-31 | $-851.85K | $-358.11K | 0.420x | +117.72% |
| 2009-12-31 | $31.68K | $-75.18K | -2.373x | -- |
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develop… Read more